The Brain & Behavior Research Foundation has announced it is awarding $10.2 million in Young Investigator Grants including for projects investigating psychedelics.
Multiple studies have shown that ketamine is a fast acting treatment for depression, but a key issue with the studies is that many participants can tell...
Diamond Therapeutics has announced that the first patient has been enrolled in its FDA-authorised UAB-Diamond trial evaluating low-dose psilocybin in patients with demoralization.
A new initiative, the PsychedeliCare Initiative, will launch in 2024 to bring citizens together to educate about psychedelics, call for the reshaping of drug policy and...
Awakn Life Sciences recently announced the completion of its feasibility study for its proprietary formulation of MDMA using Catalent’s Zydis® orally disintegrating tablet (ODT) technology.
Health Canada has given Filament Health authorisation to carry out a Phase 2 clinical trial investigating PEX010 – the company’s botanical psilocybin drug candidate – for...
New research has revealed that MDMA and methamphetamine deepen personal connections following guided conversations, and suggests different mechanisms for how these drugs produce feelings of closeness.
A team of researchers has analysed the experience of people with Obsessive-Compulsive Disorder (OCD) who have taken psychedelics, finding 30% experienced relief from their symptoms.
Results from a new analysis have revealed an improvement in mental health and cognition for Special Operations Forces veterans following a combination of psychedelic treatments.
Results from a major clinical trial have shown that esketamine outperforms one of the standard treatments for treatment-resistant major depression disorder (MDD).